This study provides compelling evidence that kinesin's stepping mechanism is governed by strain-induced conformational changes in its nucleotide-binding pockets. Using pre-steady state kinetics and ...

HCL Group founder Shiv Nadar has gifted 47 percent of his stake in HCL Corp and Vama Delhi, the promoter entities of the group, to his daughter Roshni Nadar Malhotra as part of a well-planned ...

Roshni Nadar Malhotra, the chairperson of HCL Technologies, has become the third richest Indian after inheriting 47% of her father Shiv Nadar's stake in HCL Corporation. Born in 1982 and raised in ...

Roshni Nadar Malhotra has cemented her place as India's third-richest individual following a major succession move within the HCL Group. She received 47% of her father Shiv Nadar's stake in HCL ...

Nadar—who cofounded the software giant almost five decades ago—transferred his 47% stake in HCL Corp. and Vama Delhi to Malhotra through gift deeds. This makes Malhotra the majority ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Bacteria in polymicrobial habitats are ...

LONDON, March 10 (Reuters) - While financial markets gyrate to the uncertain beat of U.S. President Donald Trump's unpredictable tariffs, physical copper traders are reaping the rewards of the ...

Mr Nadar passed the reins to his daughter, Roshni in July 2020. In a strategic succession plan, HCL Group Founder Shiv Nadar has gifted 47% of his stake in HCL Corp and Vama Sundari Investments ...

HCL Infosystems Ltd also filed a similar stock exchange. With her stakes in Vama Delhi and HCL Corp, Roshni Nadar Malhotra will become the largest shareholder of HCL Infosystems Ltd and HCL Tech.

Braemar’s second-in-command is leaving the company. Tris Simmonds is stepping down from his role as chief operating officer at the UK shipbroker with immediate effect. James Gundy’s Braemar ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. The latest ...